1. Home
  2. MNPR vs BLFY Comparison

MNPR vs BLFY Comparison

Compare MNPR & BLFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNPR
  • BLFY
  • Stock Information
  • Founded
  • MNPR 2014
  • BLFY 1939
  • Country
  • MNPR United States
  • BLFY United States
  • Employees
  • MNPR N/A
  • BLFY N/A
  • Industry
  • MNPR Biotechnology: Pharmaceutical Preparations
  • BLFY Commercial Banks
  • Sector
  • MNPR Health Care
  • BLFY Finance
  • Exchange
  • MNPR Nasdaq
  • BLFY Nasdaq
  • Market Cap
  • MNPR 209.3M
  • BLFY 194.8M
  • IPO Year
  • MNPR 2019
  • BLFY N/A
  • Fundamental
  • Price
  • MNPR $44.97
  • BLFY $9.05
  • Analyst Decision
  • MNPR Strong Buy
  • BLFY Hold
  • Analyst Count
  • MNPR 7
  • BLFY 2
  • Target Price
  • MNPR $62.00
  • BLFY $11.00
  • AVG Volume (30 Days)
  • MNPR 69.5K
  • BLFY 45.8K
  • Earning Date
  • MNPR 08-08-2025
  • BLFY 07-30-2025
  • Dividend Yield
  • MNPR N/A
  • BLFY N/A
  • EPS Growth
  • MNPR N/A
  • BLFY N/A
  • EPS
  • MNPR N/A
  • BLFY N/A
  • Revenue
  • MNPR N/A
  • BLFY $41,228,000.00
  • Revenue This Year
  • MNPR N/A
  • BLFY $20.14
  • Revenue Next Year
  • MNPR N/A
  • BLFY $20.20
  • P/E Ratio
  • MNPR N/A
  • BLFY N/A
  • Revenue Growth
  • MNPR N/A
  • BLFY N/A
  • 52 Week Low
  • MNPR $1.72
  • BLFY $8.34
  • 52 Week High
  • MNPR $54.30
  • BLFY $11.48
  • Technical
  • Relative Strength Index (RSI)
  • MNPR 59.21
  • BLFY 42.83
  • Support Level
  • MNPR $44.26
  • BLFY $9.06
  • Resistance Level
  • MNPR $47.52
  • BLFY $9.39
  • Average True Range (ATR)
  • MNPR 3.49
  • BLFY 0.23
  • MACD
  • MNPR 0.54
  • BLFY -0.05
  • Stochastic Oscillator
  • MNPR 64.49
  • BLFY 17.95

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

About BLFY Blue Foundry Bancorp

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.

Share on Social Networks: